Principal Financial Group
IMDX

Principal Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Principal Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-534
Closed -$38K – 2596
2021
Q3 		$38K Sell
534
-6,221
-92% -$572K ﹤0.01% 2547
2021
Q2 		$775K Buy
6,755
+436
+7% +$42.6K ﹤0.01% 2106
2021
Q1 		$656K Buy
6,319
+5,567
+740% +$529K ﹤0.01% 2086
2020
Q4 		$36K Buy
+752
New +$27.6K ﹤0.01% 2401

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Principal Financial Group's IMDX Position: Q4 2021 in Review

Principal Financial Group sold out of Insight Molecular Diagnostics (IMDX) in Q4 2021, closing a stake of 534 shares — an estimated $38K sold.

Principal Financial Group first reported a position in IMDX in Q4 2020 and held it in 4 quarters. The position peaked at $775K in Q2 2021. 88 funds tracked by Wall St. Rank hold IMDX as of Q4 2021.

  • Principal Financial Group reported no remaining Insight Molecular Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 534 Insight Molecular Diagnostics shares in Q4 2021, an estimated $38K.
  • Principal Financial Group first reported a position in Insight Molecular Diagnostics in Q4 2020 and held it in 4 quarters.
  • Principal Financial Group's Insight Molecular Diagnostics position peaked at $775K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.